Can a patient stable on Suboxone (buprenorphine‑naloxone) 4 mg/1 mg daily be switched to a monthly Brixadi (buprenorphine) injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Switching from Suboxone 4 mg/1 mg Daily to Monthly Brixadi

Yes, a patient stable on Suboxone 4 mg/1 mg daily can be switched directly to monthly Brixadi, but this patient does not meet the labeled indication for monthly Brixadi and should instead receive weekly Brixadi initially.

Key Issue: Dose Threshold for Monthly Formulation

According to the FDA-approved Brixadi prescribing information, monthly Brixadi is only indicated for patients currently being treated with transmucosal buprenorphine-containing products 1. However, the dosing conversion table reveals a critical limitation:

  • Patients on ≤6 mg daily sublingual buprenorphine: Only 8 mg weekly Brixadi is recommended—no monthly dose is specified 1
  • Patients on 8-10 mg daily: Can receive either 16 mg weekly OR 64 mg monthly 1

Recommended Approach

This patient should be switched to Brixadi 8 mg weekly, not monthly formulation. The FDA labeling explicitly states that monthly Brixadi is not intended for patients who are not currently receiving buprenorphine treatment, and the conversion table provides no monthly equivalent for doses ≤6 mg daily 1.

If Considering Dose Escalation First

If monthly dosing is strongly preferred for adherence or logistical reasons, consider:

  1. Increase sublingual dose to 8-10 mg daily for at least 1-2 weeks to establish stability at higher dose
  2. Then switch to Brixadi 64 mg monthly using the established conversion 1

This approach ensures the patient meets the labeled indication while achieving the desired monthly dosing interval.

Clinical Rationale

The 4 mg daily dose represents a relatively low maintenance dose. The absence of a monthly formulation for this dose range in the FDA labeling likely reflects:

  • Pharmacokinetic considerations: Lower doses may not maintain adequate plasma levels over 28 days
  • Clinical trial data limitations: The pivotal trial 2 demonstrated efficacy with weekly and monthly depot formulations, but specific low-dose monthly conversions were not established

Safety Considerations

Brixadi has demonstrated good tolerability in clinical trials, with injection site reactions occurring in approximately 18-22% of patients (none severe) 2. The depot formulation showed superior outcomes on cumulative distribution function analysis compared to daily sublingual buprenorphine 2.

Important Caveats

  • Extended-release characteristics: After steady-state (4 months for monthly), patients may have detectable plasma buprenorphine for approximately 4 months after discontinuation 1
  • Overdose reversal: Higher and repeated doses of naloxone may be necessary due to buprenorphine's long duration and high mu-receptor affinity 1
  • Recent evidence supports transitions to long-acting injectable buprenorphine within 24 hours of last sublingual dose with good tolerability 3

Practical Implementation

For this specific patient on Suboxone 4 mg/1 mg daily:

Option 1 (Preferred per labeling):

  • Switch to Brixadi 8 mg weekly
  • Administer in 7-day intervals
  • Monitor for adequacy of opioid use disorder control

Option 2 (If monthly dosing essential):

  • Increase to Suboxone 8-10 mg daily × 1-2 weeks
  • Confirm stability at higher dose
  • Switch to Brixadi 64 mg monthly
  • Administer in 28-day intervals

Both formulations (weekly and monthly) have demonstrated efficacy and may offer advantages over daily sublingual formulations in terms of treatment adherence and reducing diversion risk 2, 4, 5.

References

Related Questions

What is the conversion of an 8 mg daily dose of Suboxone (buprenorphine/naloxone) to a weekly Brixadi (buprenorphine) injection?
How can a patient who is stable on Suboxone (buprenorphine/naloxone) 8 mg daily be transitioned to a monthly long‑acting injectable buprenorphine depot?
How do you initiate buprenorphine/naloxone (Suboxone) after a buprenorphine extended‑release injection (Sublocade)?
What is the recommended induction protocol and dosing schedule for Brixadi (buprenorphine weekly) and Sublocade (buprenorphine monthly), including short‑acting buprenorphine induction, breakthrough craving management, and steps to take if injection‑site complications occur?
Can a PRN (as‑needed) dose of Suboxone (buprenorphine/naloxone) be prescribed when Brixadi (buprenorphine extended‑release injection) is not adequately controlling cravings before the next injection dose is increased?
What are the differential diagnoses for intermittent right proximal forearm pain aggravated by repetitive use, with tenderness over the dorsal/anterior proximal forearm just distal to the elbow, pain on elbow flexion, no medial or lateral epicondylar tenderness, preserved range of motion, and partial relief with diclofenac (Voltaren)?
Can a patient on Suboxone 4 mg/1 mg buprenorphine‑naloxone be switched to Brixadi (buprenorphine‑naloxone film) or Sunlocade (buprenorphine‑naloxone tablet) using the same dose and schedule?
What is the best treatment for a 66-year-old patient with alcohol-related cirrhosis and hepatitis C, bilirubin 13.5 mg/dL, INR 2.5, and hemoglobin 7 g/dL?
What is the appropriate amoxicillin dosage for a 13.43‑kg child with acute otitis media?
I have had two positive ANA screens—first showing elevated RNP antibodies (4.7 U, normal ≤0.9) with a negative ENA panel, and second with a 1:80 ANA titer and positive anti‑centromere antibodies—how concerning is this and what steps should I take?
What oral magnesium glycinate dose is appropriate to replace a serum magnesium level of 1.5 mg/dL in an adult with normal renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.